Endogenex is a clinical stage company focused on improving outcomes and quality of life for patients living with Type 2 Diabetes (T2D). Endogenex has developed a novel therapy that utilizes pulsed electric fields to promote regeneration of the duodenal mucosa for improvement in glycemic control in patients with T2D.
Location: United States
Employees: 11-50
Total raised: $150M
Founded date: 2017
Investors 3
| Date | Name | Website |
| 26.10.2023 | Lumira Ven... | lumiravent... |
| - | Intuitive ... | ventures.i... |
| 22.06.2021 | Longitude ... | longitudec... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 30.03.2026 | Series C | $50M | - |
| 01.07.2024 | Series C | $88M | - |
| 19.04.2021 | - | $12M | - |
Mentions in press and media 14
| Date | Title | Description |
| 31.03.2026 | Endogenex Secures $50 Million for Groundbreaking Diabetes Treatment | Endogenex, a cutting-edge medical technology firm, recently closed a $50 million Series C extension funding round. This significant investment pushes its total Series C financing to an impressive $138 million. The capital infusion propels t... |
| 30.03.2026 | Endogenex: $50 Million Raised For Type 2 Diabetes Treatment Technology | Endogenex, a clinical-stage medical technology company, has closed a $50 million Series C extension to support its ongoing clinical development and regulatory efforts, as detailed in its official announcement. The financing round was led by... |
| 25.03.2026 | Endogenex Raises $50M in Series C Extension Funding | Endogenex, a Minneapolis, MN-based clinical-stage medical technology company, raised $50M in Series C extension funding. The round was led by Arboretum Ventures with participation from existing investors. This extension was built on the $88... |
| 10.10.2025 | A First-of-Its-Kind Non-Surgical Procedure is Now in Clinical Trials | MINNEAPOLIS, MN, UNITED STATES, October 10, 2025 /EINPresswire.com/ -- Type 2 diabetes is one of the most significant health challenges in the U.S., affecting more than 34 million Americans — with nearly 9 million undiagnosed. Left unmanage... |
| 14.01.2025 | Endogenex™ Appoints Krissy Wright as Chief Financial Officer | Bringing finance, operational, and corporate development expertise to an experienced leadership team. MINNEAPOLIS, Jan. 15, 2025 /PRNewswire/ -- Endogenex, Inc., a clinical-stage medical device company, is proud to announce the addition of ... |
| 15.10.2024 | Endogenex™ Announces First Patient Enrolled in the ReCET Clinical Study | Achieving a Significant Clinical Milestone in Assessing the ReCET™ System as a Groundbreaking Treatment for Type 2 Diabetes MINNEAPOLIS, Oct. 15, 2024 /PRNewswire/ -- Endogenex, Inc., a clinical-stage medical device company focused on impro... |
| 06.07.2024 | Endogenex: $88 Million Raised To Improve Outcomes In Individuals With Type 2 Diabetes | Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes, announced it closed an oversubscribed Series C financing totaling $88 million. The new funding round will be used to com... |
| 01.07.2024 | Endogenex raises $88M to treat Type 2 diabetes with electricity | - |
| 25.06.2024 | Endogenex™ Announces $88 Million Series C Financing to Complete Pivotal Trial of the ReCET™ System in Patients with Type 2 Diabetes | Oversubscribed financing led by strategic investor, with participation from new and existing investors MINNEAPOLIS, June 25, 2024 /PRNewswire/ -- Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individu... |
| 25.06.2024 | Endogenex Raises $88M in Series C Financing | Endogenex, a Minneapolis, MN-based clinical-stage medical device company, raised $88M in Series C funding. Backers included Hatteras Venture Partners, Lumira Ventures, Orlando Health Ventures, Intuitive Ventures, Longitude Capital, Mayo Cli... |
Show more